David A. Cory, RPh, MBA
Chief Executive Officer, DiObex, Inc.

Mr. Cory was appointed Chief Executive Officer at DiObex in April 2007. Mr. Cory has 20 years of experience in large pharma, biotechnology, and specialty pharma with an established track record of commercial success, financial transaction, business development, and management experience.

Mr. Cory most recently served as President and Chief Operating Officer of Prestwick Pharmaceuticals, Inc., responsible for U.S. operations, creation of the company’s Canadian commercial subsidiary, and responsible for $36 million in private financing. Prior to this work at Prestwick, Mr. Cory was Chief Commercial Officer of CoTherix, Inc., where he co-led the in-licensing of the company’s lead compound and a $55 million financing. Previously, he was the Senior Vice President of Sales and Marketing at Intermune, Inc., responsible for building and managing the company’s commercial organization of 130 employees and was a key executive involved in the acquisition of 4 products and raising over $400 million in the capital markets. Mr. Cory spent the first 12 years of his career in commercial operating positions of increasing responsibility at Upjohn, Glaxo, and GlaxoWellcome across CNS, Anesthesia, Critical Care, Oncology, Infectious Disease, and Respiratory therapeutic areas. Mr. Cory has directed 10 pharmaceutical product launches and managed the commercialization of over 20 brands.

Mr. Cory is a graduate of the University of Cincinnati, College of Pharmacy, is board certified in Pharmacy, and holds a Masters Degree in Business Administration from the University of Maryland.